Filaggrin Gene Defects and the Risk of Developing Allergic Disorders  by Osawa, Rinko et al.
Allergology International Vol 60, No1, 2011 www.jsaweb.jp 1
Filaggrin Gene Defects and the Risk
of Developing Allergic Disorders
Rinko Osawa1, Masashi Akiyama2 and Hiroshi Shimizu1
ABSTRACT
Filaggrin is a key protein that facilitates terminal differentiation of the epidermis and formation of the skin bar-
rier. Mutations in the gene encoding filaggrin (FLG) have been identified as the cause of ichthyosis vulgaris (IV)
and have been shown to be major predisposing factors for atopic dermatitis (AD). Approximately 40 loss-of-
function FLG mutations have been identified in patients with ichthyosis vulgaris (IV) andor atopic dermatitis
(AD) in Europe and Asia. Major differences exist in the spectra of FLG mutations observed between different
ancestral groups. Notably, prevalent FLG mutations are distinct between European and Asian populations.
Many cohort studies on FLG mutations in AD have revealed that approximately 25-50% of AD patients harbour
filaggrin mutations as a predisposing factor. In addition, FLG mutations are significantly associated with AD-
associated asthma. The risk for developing allergic rhinitis is also significantly higher with a FLG mutation, both
with and without accompanying AD. Recent studies have hypothesized that skin barrier defects caused by FLG
mutations allows allergens to penetrate the epidermis and to interact with antigen-presenting cells, leading to
the development of atopic disorders including asthma. The restoration of skin barrier function seems a feasible
and promising strategy for prophylactic treatment of AD patients with FLG mutations.
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INTRODUCTION
Filaggrin, which is processed from profilaggrin, is a
key protein that facilitates terminal differentiation of
the epidermis and formation of the protective skin
barrier. In the outer granular layer of the epidermis,
filaggrin is associated with keratin intermediate fila-
ments and it aids their packing into bundles. In termi-
nally differentiated keratinocytes, filaggrin is cross-
linked to the cornified cell envelope, which consti-
tutes an insoluble barrier in the stratum corneum,
protecting the organism against environmental
agents and preventing epidermal water loss.1 Muta-
tions in the filaggrin gene (FLG, GenBank accession
number NM_002016) have been identified as the un-
derlying cause of the relatively common genetic kera-
tinization disorder ichthyosis vulgaris (IV; OMIM
146700), which is clinically characterized by scaling,
especially on the extensor limbs, and by palmoplantar
hyperlinearity.2-4 Although FLG is very difficult to an-
alyse because of its large size (>12 kb) and highly re-
petitive nature, a polymerase chain reaction (PCR)
strategy that permits routine and comprehensive se-
quencing of the entire coding region has recently
been developed.5 Until now, around 40 FLG muta-
tions have been reported, and the prevalent FLG mu-
tations are distinct in each population.6 Based on the
information of population-specific FLG mutations,
many cohort studies on FLG mutations in atopic der-
matitis (AD) have been performed and approximately
25-50% of patients with AD were revealed to harbour
FLG mutations as a predisposing factor.7 In several
studies, these mutations also demonstrated strong as-
sociation with other allergic phenotypes, including
asthma and allergic rhinitis.8 This article gives an
overview of FLG population genetics with respect to
AD, asthma and allergic rhinitis.
SKIN BARRIER
The skin serves numerous functions, the most obvi-
ous being its primary protective or barrier function.
The large surface area of the skin puts it in constant
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Fig.　1　Skin barrier function and allergic risk. (a) Normal skin: In the granular layer, keratohyaline 
granules composed of profi laggrin predominate. Upon terminal differentiation of keratinocytes, the 
products of degradation, fi laggrins, aggregate keratin fi laments and fl atten the keratinocytes to form 
an effective barrier against external allergens. (b) In IV and AD with FLG mutation, there is a reduc-
tion or complete absence of fi laggrin. The defective skin barrier allows external antigens to pene-
trate the epidermis, where they interact with antigen-presenting cells (Langerhans cells and dermal 
dendritic cells), which might further initiate the Th2 immune response and lead to the development 
of atopic disorders. (Modifi ed from3.)
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contact with environmental pollutants, irritants, and
allergens, and the horny layer of skin forms the major
protective barrier between the body and the environ-
ment.
The terminal differentiation of keratinocytes (Fig.
1) results in the formation of an impenetrable barrier
(the horny layer) that is the uppermost layer of the
epidermis. The successive stages of keratinocytic dif-
ferentiation in the epidermal layers are the basal cell,
spinous cell, and granular cell layers. When spinous
cells differentiate into granular cells, they begin to ac-
cumulate keratinocyte-specific proteins involved in
terminal differentiation of the horny layer.
The skin barrier of the horny layer shows three
key features: (i) intercellular lipid layers, (ii) the
cornified cell envelope and (iii) the keratin filament
network and keratohyaline granules.9 Genetic defects
in these components may result in various cutaneous
disorders, such as ichthyosis, which is characterized
by dry, thickened, scaly or flaky skin. The word “ich-
thyosis” is from the Ancient Greek, ichthys, meaning
“fish”.
The keratin filament network is an important basic
structure for maintaining the integrity and dimen-
sions of the cornified cell, and the degraded products
of the keratohyalin granules, filaggrins, aggregate the
keratin filaments in apoptosed keratinocytes into bun-
dles and promote the flattening of dead-cell rem-
nants.10-13
Abnormalities in the barrier function of the horny
layer have been hypothesized as permitting epicuta-
neous allergen exposure in atopic and asthmatic pa-
tients. Furthermore, these alterations may, in part,
help to explain the recent dramatic increase in atopic
and asthmatic disorders in humans living in industri-
alized nations.
FILAGGRIN EXPRESSION AND FUNCTION
The term ‘filaggrin’ is derived from filament aggrega-
tion protein. A giant inactive precursor, profilaggrin is
a large, complex, highly phosphorylated polypeptide
that is the main constituent of the keratohyalin gran-
ules that are visible in the granular cell layer of the
epidermis (Fig. 1). The profilaggrinfilaggrin gene
(FLG) resides on chromosome 1q21 and consists of
three exons (Fig. 2). Exon 3 is extremely large (>12
kb) and encodes most of the profilaggrin polypep-
tides with almost completely homologous 10, 11 or 12
repeats. Filaggrin is initially synthesized as profilag-
grin, a >400-kDa, highly phosphorylated, histidine-
rich polypeptide that comprises an S100 calcium-
binding domain, a B-domain and two imperfect
filaggrin-repeat domains flanking 10 to 12 essentially
identical filaggrin repeats, as well as a C-terminal do-
main (Fig. 2).14,15 On terminal differentiation of
keratinocytes, profilaggrin is dephosphorylated and
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Fig.　2　The FLG gene, which is located within the epidermal differentiation 
complex on chromosome 1q21, comprises three exons and two introns. Exon 1 
(15 bp) consists only of a 5’ untranslated (UTR) sequence, exon 2 (159 bp) 
contains the translation initiation codon, and exon 3 contains a S100 calcium-
binding domain, a B-domain and two imperfect fi laggrin-repeat domains fl ank-
ing 10 essentially identical fi laggrin repeat domains, as well as a C-terminal do-
main. There exist polymorphic variations in the number of filaggrin repeats. 
Some individuals have duplication of the 8th and/or 10th fi laggrin repeat(s).
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cleaved into 10 to 12 essentially identical 37-kd filag-
grin peptides. As mentioned above, the liberated
filaggrin subsequently and highly efficiently aggre-
gates the keratin filament, which causes the keratino-
cytes to collapse in the stratum corneum.10,13 The col-
lapsed crytoskeleton is crosslinked by transglu-
taminases to bind it to the cornified cell envelope.
Filaggrin is subsequently degraded into amino acids
that act to retain epidermal moisture.13,16 Thus, filag-
grin is a key protein during terminal differentiation
and it is essential for the formation of a normal, intact,
protective, and correctly moisturized skin barrier.9,13
FILAGGRIN DEFICIENCY CAUSED BY FLG
MUTATIONS RESULTS IN ICHTHYOSIS
VULGARIS (IV)
IV (OMIM 146700) is a common semidominant in-
herited skin disorder, estimated to affect 1 in 250 indi-
viduals. The onset is early childhood. It is character-
ized by generalized dry and scaly skin prominent on
the extensor surfaces of limbs and on the lower abdo-
men, and it is associated with palmoplantar hyper-
linearity (Fig. 3a, b).2,17 The symptoms subside dur-
ing the summer and aggravate during the winter,
when the skin tends to dry. Histologically, a decrease
in the size and number, or a complete absence, of
keratohyalin granules in the epidermis is characteris-
tic of IV. (Fig. 3c-f).2,18 An association between IV and
profilaggrin has long been suspected, but the gene
that encodes profilaggrin, FLG, proved technically
challenging to sequence. FLG resides on human
chromosome 1q21 within the so-called epidermal-
differentiation complex (EDC). The EDC is a dense
cluster of genes involved in the terminal differentia-
tion of the epidermis and the formation of the stratum
corneum, the outermost dead cell compartment of
the skin, where the main skin barrier function re-
sides.
The initiation codon of the FLG gene is located in
exon 2, although the bulk of the profilaggrin polypro-
tein in encoded by exon 3 (Fig. 2). Sequencing of
exon 3 is problematic, not only because of its size
(>12 kb) but also because it consists of between 10
and 12 tandemly arranged filaggrin repeat units.
Some individuals have duplication of the 8th andor
10th domain. The huge size, polymorphic variations in
the number of filaggrin repeats, and highly repetitive
nature prevent sequencing of the entire gene. De-
spite these difficulties, the improvement of PCR strat-
egy by the use of long-range sequencing and multiple
alignment techniques that permit comprehensive se-
quencing of the entire FLG gene have recently been
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Fig.　3　Clinicopathological features of IV. (a) Marked, adherent scales are 
clearly visible on the pretibial region of this IV patient. (b) Marked plantar hy-
perlinearity is seen in this IV patient. (c, e) Hematoxylin and eosin staining. 
Normal control skin (c) shows abundant keratohyalin granules in the granular 
layers. In contrast, the IV patient who is heterozygous for S2554X (e) shows a 
lack of granular layers in the epidermis, where basophilic substances that re-
semble keratohyalin are present in only small amounts and only intermittently. 
(d, f) In immunohistochemical staining for filaggrin, normal control skin (d) 
stains strongly. The IV patient (f) shows a marked reduction in staining for fi lag-
grin. Bar: 50 μm.
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developed.14,17 In 2006, two null mutations, R501X
and 2282del4, in the FLG gene were first identified in
patients with moderate or severe IV in 15 kindreds
from Scottish, Irish, and European-American popula-
tions.17 To date, approximately 40 loss-of-function
FLG mutations have been identified in IV andor AD
in European populations and Asian populations (Fig.
4).6,19 In addition, IV was found to exhibit semidomi-
nance, with incomplete penetrance (-90% in homozy-
gotes). The homozygotes or compound heterozy-
gotes had a severe form of IV, while the heterozy-
gotes displayed mild or no phenotype.
The genotypephenotype correlation in FLG muta-
tions has not been clarified. FLG truncation muta-
tions at any site within the profilaggrin peptide were
reported uniformly to result in severe deficiency of
profilaggrinfilaggrin processing.14 Currently, it has
been hypothesized that the profilaggrin C-terminal re-
gion is essential for proper processing of profilaggrin
to filaggrin and, eventually, truncation at any site of
profilaggrin results in abolishment of filaggrinpro-
filaggrin peptides. The hypothesis is supported by
the finding of the nonsense mutation K4022X in the
C-terminal incomplete filaggrin repeat. In the epider-
mis of patients carrying this mutation, profilaggrin
filaggrin peptides were remarkably reduced, even
though FLG mRNA expression was not reduced sig-
nificantly and the expressed mRNA included mes-
sages derived from both the wild-type alleles and the
mutant alleles.20 Histopathologically, however, the
size of keratohyaline granules in the granular layers
was decreased and immunohistochemically profilag-
grinfilaggrin peptides were remarkably reduced in
the patients’ epidermis. These observations further
support the hypothesis that the profilaggrin C-
terminal region is essential for proper profilaggrin
processing. It is now generally considered that all the
truncation mutations lead to serious loss of filaggrin
FLG Mutations in Allergic Disorders
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Fig.　4　Reported FLG mutations in a diagram of the profi laggrin peptide. Several of the mutations are 
rare, but a number of recurrent mutations have been identifi ed (bold). Note that FLG mutations in the 
European and the Asian populations appear to be unique to each population. Only two mutations 
(R501X and E2422X) were reported in both European and Asian populations. The FLG mutations 
among Asian populations are shown (red = Japanese, blue = Chinese, brown = Taiwanese, black = 
Korean). Mutations are distributed widely in the profi laggrin sequence and the mutation K4022X is the 
most distal mutation in the C-terminal incomplete fi laggrin repeat. The duplications of the 8th and 10th 
fi laggrin repeats are represented as 8-1, 8-2, 10-1 and 10-2.
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peptides, resulting in the absence of genotypephe-
notype correlations with regard to FLG mutations in
IV and AD.
PREVALENT FILAGGRIN MUTATIONS ARE
DISTINCT IN EACH RACE
To date, approximately 40 loss-of-function FLG muta-
tions have been identified in IV andor AD in Euro-
pean populations and Asian populations (Fig. 4).6,19
Mutations in FLG were initially identified in Euro-
pean families.17,21,22 To establish baseline FLG muta-
tion data for the Japanese population, we performed
FLG mutation searches in more than 30 Japanese
families with IV, after sequencing methods for the en-
tire FLG coding region had been established. We car-
ried out comprehensive sequencing of the entire FLG
coding region using an overlapping PCR strategy and
identified four Japanese-population-specific mutations
in FLG: 3321delA, S2554X, S2889X, and S3296X.23,24
In 2009, we reported two additional novel FLG muta-
tions, S1695X and Q1701X, in the Japanese popula-
tion.25 Furthermore, we studied 19 newly recruited
Japanese patients with AD and identified a novel FLG
nonsense mutation, K4022X, in one patient with AD
without any other known Japanese FLG mutation.20
In addition, one of the common European mutations,
R501X, was reported in a Japanese family.26 The
study was repeated in other Asian populations, in-
cluding Chinese,27 Taiwanese28 and Korean popula-
tions.29 Only two identical mutations (R501X and
E2422X) were reported in both European and Asian
populations.26,27 Further haplotype analysis of the
European-specific mutation R501X in the Japanese
family showed that the mutation was not inherited
from an European ancestor but occurred de novo in
Japan.26 Among Asian populations, 3321delA was
found in all four East Asian populations23,26-29 and Q
2417X was reported in Chinese and Taiwanese popu-
lations.27,28 These results have revealed the differ-
ences in filaggrin population genetics between
Europe and Asia (Fig. 4). As mentioned above, most
FLG mutations are specific to a population, such as
Europeans, Japanese, Singaporeans, Chinese, and
Taiwanese. Major differences exist in the spectra of
Osawa R et al.
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FLG mutations observed between different ancestral
groups. Prevalent FLG mutations are distinct in both
the European and the Asian populations. In addition,
there is a need to assess the ancestral admixture in
geographical regions in order to know precisely the
spectrum and preferential occurrence of FLG muta-
tions in different populations. Every population is
likely to have a unique set of FLG mutations. For mu-
tation screening, we have to obtain information on
prevalent FLGmutations in each population.
FILAGGRIN MUTATIONS CONFER STRONG
GENETIC SUSCEPTIBILITY TO ATOPIC
DERMATITIS
AD, one of the most common skin disorders, affects
15-20% of children in the developed world. AD often
presents with IV. AD is a pruritic skin disease that
typically starts early in life. The onset is during the
first 6 months of life in 45% of affected individuals, the
first year of life in 60% of affected individuals, and be-
fore 5 years of age in at least 85% of affected individu-
als.30 The hallmark of the disease is a pruritic derma-
titis that localizes in different areas depending on age.
In infancy it tends to affect the face and extensors of
the lower legs, and in childhood the flexural areas; in
adulthood the eruption has a more diffuse distribu-
tion. Other important diagnostic indications include
xerosis of the skin, early age of onset, and a chronic,
relapsing course. The incidence and prevalence of
AD decreases with increasing age. AD is thought to
have various heterogeneous etiologic factors, includ-
ing genetic predisposing factors and environmental
factors. Despite considerable efforts to elucidate
genes that confer susceptibility to AD and to clarify
the genetic background of atopic disorders, until re-
cently no strong and reproducible genetic factor has
been identified.31 Transepidermal water loss (TEWL)
and SC hydration, which are measurements of skin
barrier function, were reported to be increased in AD
patients due to their skin barrier insufficiency.32 Sig-
nificant correlations were observed between penetra-
tion rates of a hydrophilic dye and elevated IgE levels
in patients with severe AD.33 In addition, percutane-
ous penetration of sodium lauryl sulphate was re-
ported to be increased in uninvolved skin of patients
with AD.34 Taken together, these findings strongly
support the hypothesis that patients with AD have a
skin barrier defect. Three clues suggested that FLG
mutations play an important role in AD pathogenesis.
First, dermatologists have recognized that AD often
occurs in patient with IV, although the pathophysi-
ological mechanisms of this co-occurrence have not
been fully clarified.35-37 Second, the linkage of AD to
the chromosome locus on 1q21, which contains the
epidermal differentiation complex where FLG re-
sides, has been reported.38 Third, decreased filaggrin
expression has been reported in the skin of patients
with AD at both the mRNA and the protein levels.39,40
Palmer et al. first reported that decreased or ab-
sent FLG expression due to loss-of-function muta-
tions leads to impaired barrier function which mani-
fests as AD.21 They found that AD was manifested in
heterozygous carriers of two null FLG mutations,
R501X and 2282del4, with a relative risk (odds ratio)
for AD of 13.4, implying a causal relationship. There-
after, about twenty case-control analyses and eight fa-
milial analyses investigated the association between
filaggrin gene defects and AD. Most of the studies
were on Western European populations, but three
case-control studies and one family study were on a
Japanese population and one case-control study was
on a North American population.14,41-47 In the Japa-
nese population, there are at least eight FLG muta-
tions. We showed that about 27% of the patients in
our Japanese AD case series carried one or more of
these eight FLG mutations (OR: 9.94; 95%; CI: 3.77-
26.2) and that these variants were also carried by
3.7% of the Japanese general control individuals.20
Meta-analysis FLG mutation studies on AD, focusing
on the European-prevalent mutations (R501X or 2282
del4) found an overall OR of 4.78 (95%; CI: 3.31-6.92)
from the case-control studies and a summary OR of
1.99 (95%; CI: 1.72-2.31) from the family studies.8 The
strong association between FLG mutations and AD
marked a milestone in the genetic study of complex
allergic disorders. It was confirmed that the strong ef-
fect of FLG mutations on AD risk exceeds that of any
other candidate predisposing gene for AD identified
so far. Based on the information of population-specific
FLG mutations, many cohort studies of AD for FLG
mutations were performed and approximately 25-50%
of AD patients were revealed to harbour FLG muta-
tions as a predisposing factor.6
As mentioned above, every population is likely to
have a unique set of FLGmutations. Population differ-
ences highlighted by FLG mutations make it difficult
to perform worldwide screening for FLG mutations in
patients with AD. We cannot perform FLG mutation
screening in one population using the FLG mutations
reported in other populations. For example, we can-
not use the prevalent European FLG mutations when
we screen Asian patients with AE. For mutation
screening, we have to obtain information on prevalent
FLG mutations in each population. It is therefore im-
portant to establish global population genetic maps
for FLGmutations.
FLG MUTATIONS AND ASTHMA
The clinical cause of atopic disorders has been de-
scribed as an atopic or allergic march. It involves sen-
sitisation to food or aeroallergens, or both, in early
life, progressing to eczema and wheezing within the
first two years of life, and often leading to chronic
asthma, rhinitis, and other clinical manifestations of
atopic allergy in later life. Previous studies showed
that 70% of patients with severe AD developed
FLG Mutations in Allergic Disorders
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asthma, compared with 30% of patients with mild AD,
and approximately 8% of the general population.48
Previous studies in European populations have re-
ported that variants in the FLG gene are associated
with eczema and concomitant asthma41-45 or with ec-
zema alone.22 One recent meta-analysis study showed
that FLG mutations are significantly associated with
asthma (OR: 1.48; 95%; CI, 1.32-1.66). And strong ef-
fects for the compound phenotype of asthma plus ec-
zema (OR: 3.29; 95%; CI, 2.84-3.82) were observed. In
contrast, FLG mutations did not seem to be associ-
ated with asthma in the absence of eczema (OR: 1.11;
95%; CI: 0.88-1.41).49
To clarify whether FLG mutations are a predispos-
ing factor for asthma in non-European populations,
we studied 172 Japanese AE patients, 137 Japanese
asthma patients and 134 unrelated Japanese control
individuals. There is a statistically significant associa-
tion between the eight FLG mutations and AE with
asthma, and between the eight FLG mutations and
AE without asthma. In the Japanese general asthma
cohort, there was a statistically significant association
between the eight FLG mutations and asthma with
AE. There was no statistically significant association
between the FLG mutations and overall asthma pa-
tients, nor between FLG mutations and asthma with-
out AE. This Japanese cohort has a completely differ-
ent FLG mutation spectrum from those in the Euro-
pean and the North American populations. However,
our results clearly confirm the strong association of
FLG mutations with our Japanese cohort of AE pa-
tients with asthma complications, and the association
of FLG mutations and asthma patients with AE com-
plications.50
The mechanism of the asthma risk associated with
FLG null alleles is not yet fully understood. FLG is ex-
pressed in the skin and in the outer layers of the oral
and nasal mucosae, but not in the respiratory epithe-
lium of the nose or the lower airways.51,52 Therefore
it has been suggested that FLG-associated asthma is
mediated by percutaneous priming53 andor secon-
dary, possibly systemic, immunologic mechanisms
stimulated through the impaired skin barrier. Recent
studies hypothesized that skin barrier defects caused
by FLG mutations allow allergens to penetrate the
epidermis and to interact with antigen-presenting
cells (Langerhans cells and dermal dendritic cells,
which might further initiate Th2 immune response
and lead to the development of atopic disorders in-
cluding AD, asthma and allergic rhinitis.53,54
FILAGGRIN MUTATIONS AND ALLERGIC
RHINITIS
Three case-control studies investigated the associa-
tion between filaggrin gene defects and the risk of de-
veloping allergic rhinitis in people without AD.42,55,56
Recent meta-analysis study showed that FLG muta-
tions are significantly associated with allergic rhinitis
without AD (OR: 1.78; 95%; CI: 1.16-2.73). In addition,
the FLG mutations are significantly associated with
allergic rhinitis with AD (OR: 2.84; 95%; CI: 2.08-
3.88).8 Filaggrin is expressed in the anterior vestibu-
lum of the nose, but not in transitional and respira-
tory nasal epithelia.56 Thus, it seems unlikely that
FLG mutations exert organ-specific and localized ef-
fects in the upper airways. The mechanisms through
which FLG mutations contribute to airway disease
are not understood yet. Percutaneous priming and
secondary immunologic effects from the induction of
Th2 cytokines in epithelia are interesting hypotheses
that need further investigation.
NOVEL TREATMENT FOR AD BASED ON
RECENT FLG MUTATION STUDIES
The epidermal barrier dysfunction caused by FLG
mutations has been recognized as a major contribu-
tor to the pathogenesis of AD over the past few years.
The skin barrier defect is the primary event that initi-
ates disease pathogenesis, allowing the entrance of
numerous antigens into the epidermis in patients
with AD. Thus, the restoration of skin barrier func-
tion seems a feasible and promising strategy for pro-
phylactic treatment of AD patients with FLG muta-
tion. There have been efficient clinical methods to re-
store skin barrier function, including the application
of general moisturizers and specific lipid replacement
therapy.57 When used under nursing supervision,
moisturizers have been shown to reduce topical ster-
oid usage.58 In addition, the topical application of
ceramide-dominant lipid replacement therapy was
proved effective in alleviating skin barrier defects and
reducing AD severity significantly in childhood AD
patients.59
Regarding the association between filaggrin defi-
ciency and sensitization to specific antigens, allergen
exposure during early life may increase the risk of
AE, but the protective effect of reduction in allergen
exposure remains uncertain. According to a
population-based, longitudinal birth cohort study by
Henderson et al., eczema associated with FLG muta-
tions presents in early life and is persistent.60 In addi-
tion, a strong association was identified between FLG
mutations and sensitisation to grass, house dust,
mites, and cat dander. Our study revealed that AD
disease severity and specific IgE for house dust, mite
allergen, and cat dander were significantly correlated
in FLGmutation-related patients with AD.61 In light of
this, if we select patients with FLG mutations and per-
form early intervention to reinforceimprove their
skin barrier function and reduce sensitization to aller-
gens, we may achieve a significant prophylactic effect
against AD development. Further studies are re-
quired to clarify the preventive effect of early inter-
vention against AD in high-risk, filaggrin-deficient
children.
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